-
Je něco špatně v tomto záznamu ?
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024)
VG. Jokubaitis, R. Alroughani, A. Altintas, S. Eichau, S. Hughes, B. Willekens, D. Horakova, EK. Havrdova, S. Ozakbas, C. Boz, M. Habek, T. Kalincik, I. Roos, M. Etemadifar, M. Peterka, J. Lechner-Scott, JE. Meca-Lallana, Z. Rous, J. Houskova, A....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
- MeSH
- dospělí MeSH
- imunologické faktory * škodlivé účinky terapeutické užití MeSH
- komplikace těhotenství * epidemiologie farmakoterapie MeSH
- lidé MeSH
- mladý dospělý MeSH
- neuromyelitis optica * farmakoterapie epidemiologie MeSH
- novorozenec MeSH
- registrace * statistika a číselné údaje MeSH
- relabující-remitující roztroušená skleróza farmakoterapie MeSH
- roztroušená skleróza * farmakoterapie epidemiologie MeSH
- těhotenství MeSH
- výsledek těhotenství * epidemiologie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mladý dospělý MeSH
- novorozenec MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Family planning is an important aspect of multiple sclerosis (MS), and neuromyelitis optica spectrum disorder (NMOSD) management. Knowledge gaps remain, including optimal perinatal management strategies, and fetal risks associated with disease-modifying therapy (DMT) exposure. OBJECTIVE: To describe perinatal DMT use, together with pregnancy and neonatal outcomes prospectively recorded in the International MSBase Pregnancy and Women's Health Registry. METHODS: We report summary statistics for data collected between May 2020 and August 2024. RESULTS: A total of 1887 relapsing-remitting MS (RRMS), 12 primary-progressive MS (PPMS), 2 radiologically isolated syndrome (RIS) and 21 NMOSD completed pregnancies were recorded, including 1644 (85.5%) live births, 208 (10.8%) miscarriages, and 6 (0.3%) neonatal deaths. Most women had unassisted (53.8%) or assisted (7.4%) vaginal births. Seventy five percent of pregnancies had DMT exposures within 6 months preconception; 19% of NMOSD, and 62% of MS pregnancies were DMT-exposed during gestation; 18.1% of pregnancies reported in-pregnancy monoclonal antibody DMT exposure. No overt safety signals were seen. CONCLUSION: This first report from the newly launched MSBase pregnancy registry, establishes an increasing number of pregnancies being conceived on monoclonal antibody therapies. Although no safety signals were observed, it is important to continue monitoring for safety signals in real-world databases as the use of highly effective therapies continues to increase perinatally.
Al Amiri Hospital Sharq Kuwait
Center of Neuroimmunology Service of Neurology Hospital Clinic de Barcelona Barcelona Spain
CHUM MS Center and Universite de Montreal Montreal QC Canada
CORe Department of Medicine University of Melbourne Melbourne VIC Australia
Department of Biotechnological and Applied Clinical Sciences University of L'Aquila L'Aquila Italy
Department of Medicine School of Clinical Sciences Monash University Clayton VIC Australia
Department of Neurology Alfred Health Melbourne VIC Australia
Department of Neurology Antwerp University Hospital Edegem Belgium
Department of Neurology Austin Health Melbourne VIC Australia
Department of Neurology Hunter New England Health John Hunter Hospital Newcastle NSW Australia
Department of Neurology Medical Faculty Karadeniz Technical University Trabzon Turkey
Department of Neurology Monash Health Clayton VIC Australia
Department of Neurology the University of Queensland Brisbane QLD Australia
Department of Neurology University Hospital Ghent Brussels Belgium
Faculty of Medicine Isfahan university of Medical sciences Isfahan Iran
Faculty of Medicine Palacky University and University Hospital Olomouc Czech Republic
Hospital Ceske Budejovice Czech Republic
Hospital Universitario Virgen Macarena Sevilla Andalucía Spain
Hunter Medical Research Institute University of Newcastle
Institute for Immunology and Infectious Diseases Murdoch University Perth WA Australia
Izmir University of Economics Medical Point Hospital Izmir Turkey
Masaryk University Brno and University Hospital Brno Czech Republic
Multiple Sclerosis Research Association Izmir Turkey
Nemocnice Jihlava Jihlava Czech Republic
Neuroimmunology Centre Department of Neurology Royal Melbourne Hospital Melbourne VIC Australia
Personalised Medicine Centre Health Futures Institute Murdoch University Murdoch WA Australia
QEII Medical Centre Perth Australia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25022148
- 003
- CZ-PrNML
- 005
- 20251023080102.0
- 007
- ta
- 008
- 251014s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1177/13524585251349125 $2 doi
- 035 __
- $a (PubMed)40621862
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Jokubaitis, Vilija G $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia $u Department of Neurology, Alfred Health, Melbourne, VIC, Australia $1 https://orcid.org/0000000239424340
- 245 10
- $a Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024) / $c VG. Jokubaitis, R. Alroughani, A. Altintas, S. Eichau, S. Hughes, B. Willekens, D. Horakova, EK. Havrdova, S. Ozakbas, C. Boz, M. Habek, T. Kalincik, I. Roos, M. Etemadifar, M. Peterka, J. Lechner-Scott, JE. Meca-Lallana, Z. Rous, J. Houskova, A. Prat, M. Girard, R. Ampapa, K. Buzzard, O. Skibina, NA. John, AG. Kermode, MJ. Fabis-Pedrini, M. Foschi, A. Surcinelli, Y. Blanco, SM. Baghbanian, O. Gerlach, R. Macdonell, Z. Pavelek, P. Stourac, P. McCombe, G. Laureys, H. Butzkueven, A. van der Walt, O. Gray, MSBase Study Investigators
- 520 9_
- $a BACKGROUND: Family planning is an important aspect of multiple sclerosis (MS), and neuromyelitis optica spectrum disorder (NMOSD) management. Knowledge gaps remain, including optimal perinatal management strategies, and fetal risks associated with disease-modifying therapy (DMT) exposure. OBJECTIVE: To describe perinatal DMT use, together with pregnancy and neonatal outcomes prospectively recorded in the International MSBase Pregnancy and Women's Health Registry. METHODS: We report summary statistics for data collected between May 2020 and August 2024. RESULTS: A total of 1887 relapsing-remitting MS (RRMS), 12 primary-progressive MS (PPMS), 2 radiologically isolated syndrome (RIS) and 21 NMOSD completed pregnancies were recorded, including 1644 (85.5%) live births, 208 (10.8%) miscarriages, and 6 (0.3%) neonatal deaths. Most women had unassisted (53.8%) or assisted (7.4%) vaginal births. Seventy five percent of pregnancies had DMT exposures within 6 months preconception; 19% of NMOSD, and 62% of MS pregnancies were DMT-exposed during gestation; 18.1% of pregnancies reported in-pregnancy monoclonal antibody DMT exposure. No overt safety signals were seen. CONCLUSION: This first report from the newly launched MSBase pregnancy registry, establishes an increasing number of pregnancies being conceived on monoclonal antibody therapies. Although no safety signals were observed, it is important to continue monitoring for safety signals in real-world databases as the use of highly effective therapies continues to increase perinatally.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a těhotenství $7 D011247
- 650 12
- $a registrace $x statistika a číselné údaje $7 D012042
- 650 12
- $a výsledek těhotenství $x epidemiologie $7 D011256
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a novorozenec $7 D007231
- 650 12
- $a neuromyelitis optica $x farmakoterapie $x epidemiologie $7 D009471
- 650 12
- $a roztroušená skleróza $x farmakoterapie $x epidemiologie $7 D009103
- 650 12
- $a komplikace těhotenství $x epidemiologie $x farmakoterapie $7 D011248
- 650 _2
- $a mladý dospělý $7 D055815
- 650 12
- $a imunologické faktory $x škodlivé účinky $x terapeutické užití $7 D007155
- 650 _2
- $a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Alroughani, Raed $u Al Amiri Hospital, Sharq, Kuwait
- 700 1_
- $a Altintas, Ayse $u Koc University School of Medicine and Koc University Research Center for Translational Medicine, Istanbul, Turkey
- 700 1_
- $a Eichau, Sara $u Hospital Universitario Virgen Macarena, Sevilla, Andalucía, Spain
- 700 1_
- $a Hughes, Stella $u Royal Victoria Hospital, Belfast, UK
- 700 1_
- $a Willekens, Barbara $u Department of Neurology, Antwerp University Hospital, Edegem, Belgium
- 700 1_
- $a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000319150036
- 700 1_
- $a Havrdova, Eva Kubala $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Ozakbas, Serkan $u Izmir University of Economics, Medical Point Hospital, Izmir, Turkey $u Multiple Sclerosis Research Association, Izmir, Turkey
- 700 1_
- $a Boz, Cavit $u Department of Neurology, Medical Faculty, Karadeniz Technical University, Trabzon, Turkey
- 700 1_
- $a Habek, Mario $u Department of Neurology, University Hospital Center Zagreb, Zagreb, Croatia School of Medicine, University of Zagreb, Zagreb, Croatia
- 700 1_
- $a Kalincik, Tomas $u Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia $u CORe, Department of Medicine, University of Melbourne, Melbourne, VIC, Australia $1 https://orcid.org/0000000337781376 $7 xx0121848
- 700 1_
- $a Roos, Izanne $u Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia $u CORe, Department of Medicine, University of Melbourne, Melbourne, VIC, Australia $1 https://orcid.org/0000000303713666
- 700 1_
- $a Etemadifar, Masoud $u Faculty of Medicine, Isfahan university of Medical sciences, Isfahan, Iran
- 700 1_
- $a Peterka, Marek $u Faculty of Medicine and University Hospital in Pilsen, Charles University in Pilsen, Plzen, Czech Republic
- 700 1_
- $a Lechner-Scott, Jeannette $u Hunter Medical Research Institute, University of Newcastle $u Department of Neurology, Hunter New England Health, John Hunter Hospital, Newcastle, NSW, Australia
- 700 1_
- $a Meca-Lallana, Jose E $u Multiple Sclerosis CSUR, Clinical Neuroimmunology Unit, Neurology Department, Virgen de la Arrixaca Clinical University Hospital, IMIB-Arrixaca and NICEM Cathedra-UCAM-Catholic University San Antonio, Murcia, Spain
- 700 1_
- $a Rous, Zuzana $u Faculty of Medicine, Palacky University and University Hospital Olomouc, Czech Republic
- 700 1_
- $a Houskova, Jana $u Hospital Ceske Budejovice, Czech Republic
- 700 1_
- $a Prat, Alexandre $u CHUM MS Center and Universite de Montreal, Montreal, QC, Canada
- 700 1_
- $a Girard, Marc $u CHUM MS Center and Universite de Montreal, Montreal, QC, Canada
- 700 1_
- $a Ampapa, Radek $u Nemocnice Jihlava, Jihlava, Czech Republic
- 700 1_
- $a Buzzard, Katherine $u Department of Neurosciences, Eastern Health Clinical School, Box Hill Hospital, Monash University, Box Hill, VIC, Australia
- 700 1_
- $a Skibina, Olga $u Department of Neurology, Alfred Health, Melbourne, VIC, Australia $u Department of Neurosciences, Eastern Health Clinical School, Box Hill Hospital, Monash University, Box Hill, VIC, Australia
- 700 1_
- $a John, Nevin A $u Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia $u Department of Neurology, Monash Health, Clayton, VIC, Australia $1 https://orcid.org/0000000298344498
- 700 1_
- $a Kermode, Allan G $u Perron Institute for Neurological and Translational Science, University of Western Australia, Nedlands WA, Australia $u QEII Medical Centre, Perth, Australia $u Personalised Medicine Centre, Health Futures Institute, Murdoch University, Murdoch, WA, Australia $u Institute for Immunology and Infectious Diseases, Murdoch University, Perth, WA, Australia $1 https://orcid.org/0000000244764016
- 700 1_
- $a Fabis-Pedrini, Marzena J $u Perron Institute for Neurological and Translational Science, University of Western Australia, Nedlands WA, Australia $u QEII Medical Centre, Perth, Australia $u Personalised Medicine Centre, Health Futures Institute, Murdoch University, Murdoch, WA, Australia
- 700 1_
- $a Foschi, Matteo $u Department of Neuroscience, MS Center, Neurology Unit, S. Maria delle Croci Hospital of Ravenna, Ravenna, Italy $u Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
- 700 1_
- $a Surcinelli, Andrea $u Department of Neuroscience, MS Center, Neurology Unit, S. Maria delle Croci Hospital of Ravenna, Ravenna, Italy
- 700 1_
- $a Blanco, Yolanda $u Center of Neuroimmunology, Service of Neurology, Hospital Clinic de Barcelona, Barcelona, Spain
- 700 1_
- $a Baghbanian, Seyed Mohammad $u Neurology Department, Booalisina Hospital, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran $1 https://orcid.org/0000000281387504
- 700 1_
- $a Gerlach, Oliver $u Academic MS Center Zuyd, Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, the Netherlands $u Department of Neurology, School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, the Netherlands
- 700 1_
- $a Macdonell, Richard $u Department of Neurology, Austin Health, Melbourne, VIC, Australia
- 700 1_
- $a Pavelek, Zbysek $u Faculty of Medicine and University Hospital Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000217728781
- 700 1_
- $a Stourac, Pavel $u Masaryk University Brno and University Hospital, Brno, Czech Republic
- 700 1_
- $a McCombe, Pamela $u Department of Neurology, the University of Queensland, Brisbane, QLD, Australia
- 700 1_
- $a Laureys, Guy $u Department of Neurology, University Hospital Ghent, Brussels, Belgium
- 700 1_
- $a Butzkueven, Helmut $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia $u Department of Neurology, Alfred Health, Melbourne, VIC, Australia
- 700 1_
- $a van der Walt, Anneke $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia $u Department of Neurology, Alfred Health, Melbourne, VIC, Australia $1 https://orcid.org/0000000242787003
- 700 1_
- $a Gray, Orla $u South Eastern HSC Trust, Belfast, UK
- 710 2_
- $a MSBase Study Investigators
- 773 0_
- $w MED00006389 $t Multiple sclerosis $x 1477-0970 $g Roč. 31, č. 9 (2025), s. 1088-1101
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40621862 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20251014 $b ABA008
- 991 __
- $a 20251023080108 $b ABA008
- 999 __
- $a ok $b bmc $g 2417124 $s 1260311
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 31 $c 9 $d 1088-1101 $e 20250707 $i 1477-0970 $m Multiple sclerosis $n Mult Scler $x MED00006389
- LZP __
- $a Pubmed-20251014
